Abbott (NYSE: ABT) announced financial results for the third quarter ended Sept. 30, 2012. Diluted earnings per share, excluding specified items, were $1.30, reflecting 10.2 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.21, including specified items.

Bristol-Myers Squibb Company (NYSE: BMY) today announced that YERVOY® (ipilimumab), a novel immunotherapy and the first medicine approved for unresectable or metastatic melanoma in more than a decade, received the Prix Galien USA 2012 Award for Best Biotechnology Product.

Roche sales grew 4% to 33.7 billion Swiss francs thanks to strong demand for its cancer medicines and its clinical lab business. Uptake of the Group's recently launched cancer medicines Zelboraf, Erivedge and Perjeta has been positive. The Diagnostics Division maintained its global market leadership due to strong sales to hospital and private clinical laboratories.

Boehringer Ingelheim congratulates Prof. Brian Kobilka of Stanford University, who was awarded the Nobel Prize in chemistry. Prof. Kobilka has made ground-breaking contributions to the understanding of how cells sense information from the autonomic nervous system and convert them into cellular responses.

UCB announced that it has launched a third collaborative research project with Harvard that builds upon the innovative Research Alliance they both signed in 2011. The third research project named 'Mining the Human Microbiome' will be headed by Christophe Benoist, M.D., Ph.D., Dennis Kasper, M.D., and Diane Mathis, Ph.D., all Professors in the Division of Immunology in the Department of Microbiology and Immunobiology at Harvard Medical School.

World's largest pneumococcal mass vaccination programme is expected to protect up to 4.8 million children in Pakistan from pneumococcal disease. Pakistan is the first GAVI eligible country in south Asia to introduce pneumococcal vaccines.

Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.